Publications
A commercial rapid host-response test in COVID-19 severity stratification and triage
In a late-breaker presentation onsite, Immunexpress collaborators at Hospital Foch, France evaluated the performance of SeptiCyte® RAPID using patient samples from COVID-19 positive cases, in a study supported by Immunexpress partner Biocartis and the Biomedical Advanced Research and Development Authority (BARDA).
Read MoreComparison of Lactate, Procalcitonin and a Gene Signature Assay Alone or in Combination to Differentiate Sepsis from Infection Negative Systemic Inflammation in ICU Patients
Use of SeptiCyte® RAPID Assay to Assess the Risk of ICU admission in COVID-19 Patients
ECCMID_P04984_REVIEW_21June2021
Read MoreSeptiCyte® RAPID in Sepsis Cases with Malignancies or Treated with Anitneoplastics/Immunosuppressants
A study showing the performance of SeptiCyte RAPID in patients with malignancies and/or on anti-neoplastic or corticosteroid therapies. IMM-009-SCCM-04-01-SC
Read MoreA Fully Integrated Diagnostic Test to Discriminate Sepsis from Infection-Negative Systemic Inflammation
Sepsis is a serious medical condition that manifests with a dysregulated immune response to an infection in the bloodstream, and is a major cause of morbidity and mortality worldwide. Many non-infectious conditions can lead to a state of hyper-inflammation known as the systemic inflammatory response syndrome (SIRS), which clinically can look very similar to sepsis.…
Read MoreIn Silico Performance of a Rapid Sepsis Test in Patients with Candidemia
SeptiCyte® RAPID differentiated patients with candidemia from those with INSI/SIRS, not infected and healthy subjects
Read MoreComparison of a Cartridge-Based Host Gene Expressions Test to a Manual Method for Use in the Diagnosis of Sepsis
SeptiCyte® RAPID test is a rapid, repeatable, reproducible, near-patient, immune-response sepsis diagnostic, providing accurate results in ~ 1 hr to differentiate sepsis from SIRS
Read MoreBlood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study
Abstract Background There is an urgent need to develop biomarkers that stratify risk of bacterial infection in order to support antimicrobial stewardship in emergency hospital admissions. Methods We used computational machine learning to derive a rule-out blood transcriptomic signature of bacterial infection (SeptiCyte™ TRIAGE) from eight published case-control studies. We then validated this signature by…
Read MoreModeling Improved Patient Management and Hospital Savings with SeptiCyte™ LAB in the Diagnosis of Sepsis at ICU Admission
Background: The ability to accurately diagnose sepsis at ICU admission is key to effective clinical management, patient safety, and efficient hospital resource utilization. Most tests used for sepsis diagnosis, including pathogen detection and host-based biomarker approaches, are lacking in either sensitivity or specificity, resulting in a clinical assumption of sepsis, patient overtreatment with antimicrobials, and…
Read MoreA pilot study of a novel molecular host response assay to diagnose infection in patients after high-risk gastro-intestinal surgery
SeptiCyte LAB measures the expression of four host-response RNAs in peripheral blood to distinguish sepsis from sterile inflammation. This study evaluates whether sequential monitoring of this assay has diagnostic utility in patients after esophageal surgery. Among 370 esophagectomy patients, 120 (32%) subjects developed a complication requiring ICU (re)admission, 63 (53%) of whom could be analyzed.…
Read More